{"id":"W2163450464","doi":"10.1200/jco.2014.59.2139","title":"Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20<sup>+</sup> Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":154,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"BC Cancer Agency; Weill Cornell Medical College; Houston Methodist Research Institute; Università di Bologna; Queen's University; National Cancer Institute; University of Rochester; University of Toronto; Memorial Sloan-Kettering Cancer Center; F. Hoffmann-La Roche; Sveučilište u Zagrebu; Pharmacyclics; Genentech; Università degli Studi del Piemonte Orientale; Celgene","keywords":"Obinutuzumab; Medicine; Rituximab; CD20; Lymphoma; Internal medicine; Oncology; Nuclear medicine","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005759041,0.0003261211,0.005766459,0.0004432619,0.00007462882,0.00001535731,0.0003227307,0.0002629363,0.00002897377],"category_scores_gemma":[0.001675667,0.0001537403,0.001041894,0.0008818718,0.0003773406,0.0001201599,0.0001392398,0.0005577585,0.00000322993],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00101476,"about_ca_system_score_gemma":0.00389481,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002740895,"about_ca_topic_score_gemma":0.0002285303,"domain_scores_codex":[0.9922882,0.001882358,0.003901511,0.0003701227,0.001217871,0.0003399048],"domain_scores_gemma":[0.9921346,0.002518571,0.003581136,0.0005013432,0.0008193961,0.0004450002],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5811405,0.09005007,0.3185064,0.000008015765,0.00390182,0.0002711918,0.0009518921,0.001197431,1.980045e-7,0.000003137505,0.0001873981,0.003782],"study_design_scores_gemma":[0.7151914,0.08914223,0.1817399,0.0001265765,0.01063556,0.00001567253,0.0005510519,0.002297098,0.00001189501,0.000007145819,0.0001661993,0.000115194],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9962193,0.0001001971,0.00003288555,0.0004520689,0.0003677933,0.002218411,0.000006560491,0.000005809972,0.0005969648],"genre_scores_gemma":[0.9987317,0.00002852526,0.0005927454,0.0002749185,0.0002247407,0.00005941674,0.00001078366,0.00002191421,0.0000552772],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1367664,"threshold_uncertainty_score":0.6909225,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1019630916029561,"score_gpt":0.4113322242863002,"score_spread":0.309369132683344,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}